GlassScriptPhysician profile
Stacey E Gorovoy
NPI 1255483822
$2,862.50
in general payments reported to CMS, 2019-2025
26 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $118 · 2021: $64.34 · 2022: $201 · 2023: $828 · 2024: $580 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.06 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $389.83 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $354.81 | 2021-2025 | Argos, Rocklatan, Tryptyr |
| Dompe US, INC. | $231.38 | 2019-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $177.20 | 2022-2023 | Syfovre |
| Astellas Pharma US INC | $168.39 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $125.67 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $116.73 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $112.43 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $97.04 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $90.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.91 | 2019-2023 | |
| Oyster Point Pharma, INC. | $67.56 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $57.75 | 2024-2025 | Vevye |
| Allergan, INC. | $51.76 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.24 | 2022-2023 | Vabysmo |
| Ocular Therapeutix, INC. | $35.18 | 2019-2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.21 | 2019 | |
| Aerie Pharmaceuticals, INC. | $21.42 | 2020 | |
| Rayner Intraocular Lenses Limited | $21.25 | 2025 | Omidria |
| Mallinckrodt Hospital Products INC. | $21.12 | 2023 | Acthar |
| Iridex Corporation | $19.57 | 2020 | |
| Shire North American Group INC | $17.84 | 2019 | |
| Eyevance Pharmaceuticals LLC | $16.95 | 2019 | |
| Horizon Therapeutics Plc | $16.82 | 2023 | Tepezza |
| Amgen INC. | $13.91 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Gorovoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.